|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Retevmo
|
|
gptkbp:activities
|
RET inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2020
gptkb:FDA
|
|
gptkbp:associated_with
|
gptkb:Loxo_Oncology
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:class
|
targeted therapy
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
positive efficacy in RET-altered tumors
|
|
gptkbp:contraindication
|
hypersensitivity to selpercatinib
|
|
gptkbp:developed_by
|
gptkb:Loxo_Oncology
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
September 2020
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
selpercatinib
|
|
gptkbp:indication
|
gptkb:healthcare_organization
gptkb:medullary_thyroid_cancer
gptkb:papillary_thyroid_cancer
|
|
gptkbp:ingredients
|
gptkb:selpercatinib
C22 H24 Cl N5 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_available_in
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:is_monitored_by
|
electrolytes
blood pressure
liver function tests
|
|
gptkbp:is_used_for
|
treatment of RET-mutant medullary thyroid cancer
treatment of RET fusion-positive non-small cell lung cancer
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
brand name Retevmo
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
bottles of 30 tablets
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:research_focus
|
RET alterations
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
diarrhea
hepatotoxicity
|
|
gptkbp:type_of
|
1394640-09-0
|